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Abstract
Cerebral small vessel disease (CSVD) is considered to be caused by an increased permeability of the blood-brain barrier and results in
enlargement of Virchow Robin spaces (VRs), white matter lesions, brain microbleeds, and lacunar infarcts. The increased permeability of
the blood-brain barrier may relate to endothelial cell activation and activated monocytes/macrophages. Therefore, we hypothesized that
plasma markers of endothelial activation (adhesion molecules) and monocyte/macrophage activation (neopterin) relate to CSVD manifes-
tations. In 163 first-ever lacunar stroke patients and 183 essential hypertensive patients, we assessed CSVD manifestations on brain magnetic
resonance imaging (MRI) and levels of C-reactive protein (CRP), neopterin, as well as circulating soluble adhesion molecules (sICAM-1,
sVCAM-1, sE-selectin, sP-selectin). Neopterin, sICAM-1 and sVCAM-1 levels were higher in patients with extensive CSVD manifestations
than in those without (p  0.01). Neopterin levels independently related to higher numbers of enlarged Virchow Robin spaces (p  0.001).
n inflammatory process with activated monocytes/macrophages may play a role in the increased permeability of the blood brain barrier
n patients with CSVD.
2012 Elsevier Inc.
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Cerebral small vessel disease (CSVD) poses major chal-
lenges for physicians in the aging population. CSVD has a
high morbidity: it relates to (recurrent) ischemic stroke (de
Jong et al., 2002), cognitive disturbance (Reed et al., 2004;
Tullberg et al., 2004; Wen et al., 2004) and cognitive de-
cline (Garde et al., 2005; van Dijk et al., 2008), gait distur-
bances (Baezner et al., 2008), and urinary problems
(Poggesi et al., 2008). CSVD relates to vascular risk factors
like increasing age (van Dijk et al., 2008; Wiszniewska et
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Open access under the Elsevier OA license.al., 2000) and hypertension (Boiten et al., 1993). However,
effective therapies to reduce the burden of CSVD are
lacking up until now, because the unraveling of the
pathophysiological mechanisms leading to CSVD has
only just started.
The pathogenesis of CSVD probably starts with an
increase in permeability of the blood-brain barrier (Far-
rall and Wardlaw, 2009) with enlargement of Virchow
Robin spaces (perivascular spaces), (a)symptomatic la-
cunar infarcts, white matter lesions (WML), and microb-
leeds as sequelae (Rouhl et al., 2009b; Vernooij et al., 2008;
Wardlaw et al., 2003). The blood-brain barrier is maintained
by the interplay between endothelial cells, pericytes, and
astrocytes. Endothelial dysfunction could, therefore, lead to
an increase in blood-brain barrier permeability. Indeed, in
patients with WML, levels of soluble adhesion molecules,
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hesion molecule-1 (sICAM-1) (Hassan et al., 2003), sP-
selectin (de Leeuw et al., 2002), and vascular cellular ad-
hesion molecule-1 (sVCAM-1) (de Leeuw et al., 2002),
which are markers of endothelial dysfunction (Deanfield et
al., 2007), are elevated. However, the cause of the endothe-
lial dysfunction remains unclear.
Adhesion molecules are expressed by endothelial cells in
increased amounts on activation. They enable interaction
with circulating leukocytes (Ghosh et al., 1998). In patients
with vascular diseases such as atherosclerosis and vasculitis,
levels of circulating soluble adhesion molecules are ele-
vated (Lind, 2003; Tervaert and Kallenberg, 1997). As a
result of the leukocyte-endothelial interactions, both endo-
thelial cells and leukocytes (e.g., monocytes) become in-
creasingly activated (Schubert et al., 2010). Activated
monocytes/macrophages produce neopterin as well as cyto-
kines which induce liver cells to produce C-reactive protein
(CRP) (Fuchs et al., 1992). Neopterin and CRP levels are
elevated in patients with vascular disease, and relate to a
higher risk of ischemic events (van Haelst et al., 2003).
Furthermore, neopterin may itself induce endothelial dys-
function with increased expression of adhesion molecules as
a consequence (Cirillo et al., 2006).
We hypothesized that patients with CSVD have higher
levels of neopterin, CRP, and soluble adhesion molecules,
than patients without. To test our hypothesis, we selected
patients with a high prevalence of CSVD: first-ever lacunar
stroke patients as well as essential hypertensive patients.
2. Methods
2.1. Patients
Patients included in our study participated in 2 larger
studies, the lacunar stroke patients in a longitudinal study on
biological determinants of CSVD, whereas the hypertensive
patients participated in a study on brain damage in hyper-
tension.
All 280 first-ever lacunar stroke patients (event between
May 2003 and December 2007) who were registered in the
prospective Maastricht Stroke Registry were eligible for
inclusion in the study. This registry is a hospital-based
database including all stroke patients over the age of 18
years with symptoms lasting longer than 24 hours. We
defined lacunar stroke as an acute stroke syndrome with a
lesion on imaging compatible with the occlusion of a single
perforating small artery, consisting of a subcortical, demar-
cated lesion with a diameter  20 mm on magnetic reso-
nance imaging (MRI). If no such lesion was visible, we used
established clinical criteria for lacunar stroke (de Jong et al.,
2002). Furthermore, causes other than CSVD (cardiac em-
bolic source, cerebral large vessel disease, carotid stenosis
on Duplex imaging; de Jong et al., 2002) or history of
ystemic vasculitis or malignant disease had to be excluded.Altogether, 163 patients were willing and able to partici-
pate.
Essential hypertensive patients were recruited from the
outpatient department of Internal Medicine. At their inclu-
sion, these patients were free of any symptomatic ischemic
or vascular disease, or other comorbidity like atrial fibrilla-
tion, chronic renal disease, systemic vasculitis or malignant
disease (Henskens et al., 2008). Of the 389 eligible patients,
183 were willing and able to participate in the present study.
Forty-three patients who visited the neurological outpa-
tient department with myogenic back pain or entrapment
neuropathies served as controls. They had no vascular or
inflammatory disease, no hypertension, and no silent isch-
emic lesions on cerebral MRI.
Vascular risk factor profiles were recorded for all partic-
ipants. For the lacunar stroke patients, we defined charac-
teristics based on values obtained after the acute phase (at or
around 3 months after the stroke). We defined hypertension
as known hypertension, treated or not, or at least 2 blood
pressure recordings  140/90 mm Hg; diabetes mellitus as
known diabetes, treated or not, or fasting serum glucose 
7 mmol/L, or a postprandial level  11 mmol/L on at least
2 separate occasions; coronary artery disease as known or
treated angina pectoris, the presence of myocardial infarc-
tion, or typical electrocardiogram (ECG) changes; hyper-
cholesterolemia as known high cholesterol levels, treated or
known, or fasting total cholesterol levels of  5.0 mmol/L;
and peripheral vascular disease as known intermittent clau-
dication, leg ischemia at rest, or amputation as a conse-
quence of peripheral vascular disease.
2.2. Procedures
To prevent confounding by acute phase responses, all
lacunar stroke patients underwent the procedures mentioned
below at or around 3 months after their stroke.
2.2.1. MRI of the brain
We used 1.5 Tesla imaging with both standard T2-
weighted, fluid-attenuated inversion-recovery (FLAIR) and
gradient echo sequences (Rouhl et al., 2009a). Images were
assessed by consensus by 2 experienced neurovascular re-
searchers (RPWR and RJvO) as described earlier (Rouhl et
al., 2008); in case of disagreement, the judgment of a third
(JL) was decisive. We counted silent lacunar infarcts (with
diameter  20 mm; hyperintense lesions on T2 imaging
with corresponding hypointense lesion with hyperintense
rim on fluid-attenuated inversion-recovery images) and
deep and/or superficial microbleeds (small, 5 mm hypoin-
tensities on gradient echo imaging, not representing calci-
fications or superficial blood vessels). We used the Fazekas
scale to estimate the extent of the periventricular and deep
WML (Fazekas et al., 1987). Extensive WML were defined
as a score of 3 (periventricular hyperintensities with in-
volvement of white matter) on the periventricular scale,
and/or a score of 2 or 3 on the deep white matter scale
(beginning confluence of lesions or large confluent lesions).
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bral small vessel disease (Rouhl et al., 2008), namely en-
larged Virchow Robin spaces at 3 different levels (basal
ganglia, linear spaces at sella media level, and punctuate
spaces at centrum semiovale level). These were assessed for
both hemispheres together using a predefined 3-point scale:
(1) 20; (2) between 20 and 50; and (3) 50 (Rouhl et al.,
2008).
2.2.2. Blood
Blood was sampled from an antecubital vein into
5-mL serum as well as 4-mL (ethylenediaminetetraacetic
acid [EDTA]) plasma tubes (BD Biosciences, Breda, the
Netherlands). Plasma was separated from the blood cells
within 2 hours and stored at -70 °C whereas serum was
stored at -20 °C until analysis.
2.2.3. Measurements of adhesion molecules: sVCAM-1,
sICAM-1, sP-selectin, and sE-selectin
sVCAM-1, sICAM-1, sP-selectin, and sE-selectin were
all measured using commercially available enzyme-linked
immunosorbent assay (ELISA) kits (BioSource, Europe,
Nivelles, Belgium) following manufacturer’s instructions.
Results are expressed as ng/mL. Intra-assay variability was
3.1%, 4.1%, 2.4%, and 5.4%, whereas interassay variability
was 5.2%, 7.7%, 5.2%, and 6.0% for sVCAM-1, sICAM-1,
sP-selectin, and sE-selectin respectively.
2.2.4. Measurement of neopterin and high sensitivity (hs)
CRP
Neopterin was measured using commercially-available
enzyme-linked immunosorbent assay (ELISA) kits (IBL,
Hamburg, Germany), following manufacturer’s instruc-
tions. Data are expressed as ng/mL; for this test, intra-assay
variability was 3.6%, whereas interassay variability was
7.2%. hsCRP was determined with nephelometry, using the
BN ProSpec (Siemens, Erlangen, Germany) using a previ-
ously described protocol (Rothkrantz-Kos et al., 2003); data
are expressed as mg/L. Intra-assay variability was 1.4%, and
interassay variability was 0.9%.
2.3. Statistical analysis
First, in our primary unadjusted analysis, we compared
levels of neopterin, hsCRP, and adhesion molecules (using
Mann-Whitney tests) between all patients with or without
(1) asymptomatic lacunar infarcts; (2) extensive WML; and
(3) both asymptomatic lacunar infarcts in combination with
extensive WML. In this analysis, we considered all lacunar
stroke patients as well as all hypertensive patients together,
which is in line with other studies in CSVD patients (like
the Leukoaraiosis And DISability [LADIS] and Atheroscle-
rosis Risk in Communities [ARIC] studies), assuming that
the pathophysiology of CSVD manifestations is similar,
regardless of the underlying disease (Gottesman et al., 2010;
van Straaten et al., 2006). In a secondary unadjusted anal-
ysis, we considered the lacunar stroke patient group and
hypertensive patient group separately. We used values fromhealthy controls as a reference for “normal” levels (without
testing statistically, as we did not have a hypothesis regard-
ing a difference between patients and controls). We also
assessed unadjusted correlations (using Spearman’s rho)
between the adhesion molecules, hsCRP and neopterin.
Second, in our multivariate analysis we adjusted for
possible confounders (age, sex, and vascular risk factor
profile). In this analysis we tried to determine whether there
were independent relations between adhesion molecules,
neopterin or hsCRP on 1 hand and MRI characteristics of
CSVD (asymptomatic lacunar infarcts, extensive white mat-
ter lesions, brain microbleeds and enlarged Virchow Robin
spaces [VRs]) on the other, using linear regression analysis.
We used log-transformation to correct for nonnormality of
the data (neopterin and the adhesion molecules). Unless
indicated otherwise, we considered a p value  0.05 statis-
tically significant. All analyses were performed using SPSS
version 16 (Statistical Package for the Social Sciences;
Chicago, IL, USA).
2.4. Ethical considerations
The study was approved by the Medical Ethical Com-
mittee of the Maastricht University Medical Centre. All




Patient characteristics as well as vascular risk factor
profiles are shown in Table 1. Of the lacunar stroke patients,
104 had asymptomatic lacunar infarcts, and 59 had exten-
sive WML, whereas of the hypertensive patients, 13 had
asymptomatic lacunar infarcts, and 22 had extensive WML.
As per definition, none of the control subjects had asymp-
Table 1












63.9 (12.0) 55.3 (11.9) 62.0 (7.7)
Male sex 100 (61.0) 96 (52.5) 20 (45.5)
Hypertension 107 (65.2) 183 (100.0) 0 (0.0)
Coronary artery
disease
23 (14.0) 19 (10.4) 0 (0.0)
Peripheral vascular
disease
6 (3.7) 4 (2.2) 0 (0.0)
Diabetes 19 (11.6) 6 (3.3) 0 (0.0)
Hypercholesterolemia 129 (78.7) 72 (39.3) 10 (22.7)
Current smoking 62 (37.8) 35 (19.1) 13 (30.2)
Statin use 140 (85.4) 69 (37.7) 3 (6.8)
Antihypertensive use 110 (67.1) 163 (89.1) 0 (0.0)
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molecules, neopterin, and hsCRP
In our first, unadjusted, analysis, we compared levels of
inflammatory markers and adhesion molecules in patients
with or without silent lesions on MRI. As shown in Table 2,
patients with asymptomatic lacunar infarcts had higher lev-
els of neopterin, sP-selectin, and sICAM-1 as well as sV-
CAM-1 than those without, whereas hsCRP and sE-selectin
levels did not differ. When we compared patients with
extensive WML with those without, the first had higher
levels of neopterin and sVCAM-1. When patients with both
asymptomatic lacunar infarcts as well as extensive WML
were compared with those without both these types of
lesions, neopterin, sICAM-1, and sVCAM-1 levels were
higher in the first group. Neopterin as well as sVCAM-1
levels were similar in patients without CSVD manifesta-
tions as compared with healthy controls.
In a second unadjusted analysis, when considering lacu-
nar stroke patients or hypertensive patients separately, only
neopterin levels differed between those with or without
asymptomatic lacunar infarcts only in patients with lacunar
stroke (p  0.04) and not in essentially hypertensive pa-
tients (p  0.10).
3.3. Correlations between the different adhesion
molecules, neopterin, and hsCRP
In general, all adhesion molecules, neopterin, and hsCRP
correlated significantly with each other, though correlation
coefficients are relatively low (Spearman rho ranges from
0.10 to 0.30). Only sVCAM-1 and neopterin had a rho of
0.30, with p  0.001.
3.4. Multivariate analyses: neopterin and E-selectin
independently relate to CSVD manifestations
We determined significant independent relations be-
tween the levels of adhesion molecules, inflammatory mark-
Table 2
Median levels (with interquartile range within parentheses) of hsCRP, neo







hsCRP (mg/L) 2.13 (4.14) 1.90 (3.19) 1.95 (4.09
Neopterin (ng/mL) 2.01 (1.96)*** 1.65 (0.62) 1.97 (1.01
sP-selectin (ng/mL) 54.6 (62.1)* 42.9 (46.9) 45.3 (58.8
sE-selectin (ng/mL) 24.2 (23.3) 25.0 (21.3) 28.4 (24.6
sICAM-1 (ng/mL) 548.7 (219.4)*** 459.7 (192.0) 517.3 (176.
sVCAM-1 (ng/mL) 731.6 (274.5)** 687.9 (212.3) 758.3 (305.
Data are median (interquartile range). Statistically significant differences
Key: CRP, C-reactive protein; hs, high sensitivity; WML, white matter le
* p  0.05 (yes vs. no).
** p  0.01.
***p  0.001.ers, and CSVD manifestations using linear regression anal- (yses. The only association that remained significant after
correction for age, sex, pre-existent large vessel disease
(coronary artery disease or peripheral artery disease), as
well as patient group (hypertensive or lacunar stroke pa-
tient), was that between higher neopterin levels and higher
numbers of enlarged Virchow Robin spaces at the level of
the basal ganglia (  0.257; p  0.001), and that between
higher sE-selectin levels and higher number of microbleeds,
irrespective of their location (deep or superficial) ( 
.155; p  0.045).
. Discussion
We found higher levels of neopterin in patients with
symptomatic lacunar infarcts as well as in patients with
hite matter lesions, than in those without these lesions.
urthermore, higher levels of sP-selectin, sE-selectin, and
ICAM related to CSVD manifestations. However, most
mportantly, we found that after correction for vascular risk
actors, neopterin levels related independently to higher
umbers of enlarged Virchow Robin spaces at the levels of
he basal ganglia. As neopterin is a marker of activated
onocytes/macrophages our data suggest that activated
onocytes/macrophages play a role in the pathophysiology
f CSVD.
Limited data are available on neopterin in CSVD. In the
cute phase of stroke, neopterin levels increase (Grau et al.,
001). However, there are no data on neopterin in the
hronic phase after stroke or in relation to WML. We
emonstrated that neopterin levels are higher in lacunar
troke patients than in hypertension patients. Furthermore,
e found a relation between higher neopterin levels and
igher numbers of enlarged Virchow Robin spaces at the
asal ganglia level, which suggests a relation between
onocyte/macrophage activation and CSVD. Neopterin is a
roduct of activated monocytes/macrophages and it stimu-
ates both the immune response as well as the endothelium












1.94 (2.59) 2.21 (4.30) 1.92 (3.12) 2.70 (4.04)
1.71 (0.70) 2.05 (1.05)*** 1.63 (0.62) 1.70 (0.66)
47.3 (47.5) 45.6 (63.1) 42.8 (45.6) 62.0 (54.5)
24.1 (20.4) 28.9 (26.2) 24.6 (22.3) 28.8 (15.0)
473.7 (218.8) 509.7 (171.7)** 453.6 (187.8) 524.3 (99.3)










sions.Hoffmann, 2007). Together with other products of acti-
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clear factor kappa-B, a transcription factor which induces
endothelial activation with increased expression of adhesion
molecules as a consequence (Cirillo et al., 2006). Endothe-
lial activation in CSVD could result in increased permea-
bility of the blood-brain barrier and induction of an inflam-
matory reaction, leading to dilation of the perivascular
spaces. Enlargement of the Virchow Robin spaces coincides
with inflammatory activity in multiple sclerosis (as evi-
denced by contrast enhancing lesions elsewhere in the
brain) (Wuerfel et al., 2008). Thus, the independent relation
between neopterin levels (activated monocytes/macro-
phages) and number of enlarged Virchow Robin spaces at
the basal ganglia level suggests that there may be an in-
flammatory reaction in CSVD in which activated mono-
cytes/macrophages play a role.
Strikingly, CRP values were not elevated in patients with
CSVD manifestations, which contrasts with earlier obser-
vations (Schmidt et al., 2006). CRP is produced in response
to interleukin-6 production by several types of cells among
which are monocytes/macrophages. Neopterin, on the other
hand, is produced solely by monocytes/macrophages as a
result of stimulation by interferon-gamma, which, in turn, is
produced by T-cells (Schroecksnadel et al., 2006). Because
we observed a differential upregulation of inflammatory
markers, activated T-cells could also be involved in CSVD.
Importantly, in our study we avoided the pitfall of known
causes for higher neopterin levels: increasing age, autoim-
mune disease (like antineutrophil cytoplasmic antibody
[ANCA]-associated vasculitis; Muller Kobold et al., 1999),
malignant disease, and infections (Fuchs et al., 1992). Ex-
cept for these conditions, neopterin levels are fairly stable
over time (van Haelst et al., 2003).
The inflammatory response we found could also relate
to endothelial cell activation and dysfunction. Previously,
others also demonstrated elevated levels of soluble ad-
hesion molecules in patients with CSVD. In nondiseased
subjects, sICAM-1 levels related to the extent of WML,
independent of hypertension and age (Han et al., 2009).
Furthermore, sICAM-1 levels are elevated after a lacunar
stroke (Knottnerus et al., 2009), and higher sICAM-1
levels related to early neurological deterioration and
worse outcome at 3 months (Castellanos et al., 2002). In
lacunar stroke patients, sICAM-1 levels were higher in
those with WML than in those without (Hassan et al.,
2003). Moreover, in a community-based sample, higher
sICAM-1 levels related to progression of WML and la-
cunar infarcts after 3 and 6 years (Markus et al., 2005).
Thus, sICAM-1 seems to be an important disease marker
in lacunar stroke and white matter lesions. However, the
origin of sICAM-1 is heterogeneous: it may derive from
endothelium, but also from activated monocyte/macro-
phages or from other cells such as smooth muscle cells
(Constans and Conri, 2006). This may be the reason why
earlier cross-sectional studies could not unequivocallydemonstrate endothelial involvement in CSVD. We con-
firmed elevated sICAM-1 levels in patients with WML
and lacunar infarcts, but unlike the aforementioned stud-
ies, we did not find an independent relation between
sICAM-1 and manifestations of CSVD. This could be a
result of our blood sampling protocol, as we avoided
acute phase responses after stroke by postponing blood
sampling and excluded patients with concomitant dis-
eases. Also, we found an independent relation between
sE-selectin and the number of microbleeds. sE-selectin
provides the most valid indication of endothelial involve-
ment, because its source is exclusively endothelial
(Deanfield et al., 2007). Therefore, the independent
relation between sE-selectin and the number of microb-
leeds strongly suggests activation of endothelial cells in
CSVD.
Our study has several limitations. First, we confined
stroke patient selection to those with lacunar stroke and
hypertension, and therefore we are not able to generalize
our findings to patients with other causes of stroke
(atherothrombotic or cardioembolic) or white matter dis-
ease. Second, our study is cross-sectional, and therefore
no firm conclusions can be drawn with regard to causal-
ity. Third, patient selection favored younger patients in
the lacunar stroke group. However, this selection would
rather lead to an underestimation of associations. Not-
withstanding these limitations, the strengths of our study
remain that we studied a large group of well character-
ized patients, and that we excluded effects of an acute
phase response.
In conclusion, our study provides evidence for the in-
volvement of activated monocytes/macrophages in cerebral
small vessel disease. Though mechanisms have yet to be
determined and our results need confirmation in other pop-
ulations, this could be relevant for pathophysiological con-
cepts of cerebral small vessel disease, and might lead to
more effective therapeutic strategies to reduce the burden of
CSVD in the aging population.
Disclosure statement
All authors report that they do not have conflicts of
interest.
The study was approved by the Medical Ethical Com-
mittee of the Maastricht University Medical Centre. All
patients and control subjects gave their written informed
consent.
Acknowledgements
This work was supported by the Netherlands Heart Foun-
dation (2005B022 to RPWR), the Netherlands Thrombosis
Foundation (2007-3 to ILHK) and the Novartis Foundation
for Cardiovascular Excellence (003/07 to LHGH).
1805R.P.W. Rouhl et al. / Neurobiology of Aging 33 (2012) 1800–1806References
Baezner, H., Blahak, C., Poggesi, A., Pantoni, L., Inzitari, D., Chabriat, H.,
Erkinjuntti, T., Fazekas, F., Ferro, J.M., Langhorne, P., O’Brien, J.,
Scheltens, P., Visser, M.C., Wahlund, L.O., Waldemar, G., Wallin, A.,
Hennerici, M.G., LADIS Study Group, 2008. Association of gait and
balance disorders with age-related white matter changes: The LADIS
study. Neurology 70, 935–942.
Boiten, J., Lodder, J., Kessels, F., 1993. Two clinically distinct lacunar
infarct entities? A hypothesis. Stroke 24, 652–656.
Castellanos, M., Castillo, J., García, M.M., Leira, R., Serena, J., Chamorro,
A., Dávalos, A., 2002. Inflammation-mediated damage in progressing
lacunar infarctions: A potential therapeutic target. Stroke 33, 982–987.
Cirillo, P., Pacileo, M., DE Rosa, S., Calabrò, P., Gargiulo, A., Angri, V.,
Granato-Corigliano, F., Fiorentino, I., Prevete, N., DE Palma, R.,
Mauro, C., Leonardi, A., Chiariello, M., 2006. Neopterin induces
pro-atherothrombotic phenotype in human coronary endothelial cells. J.
Thromb. Haemost. 4, 2248–2255.
Constans, J., Conri, C., 2006. Circulating markers of endothelial function
in cardiovascular disease. Clin. Chim. Acta 368, 33–47.
de Jong, G., Kessels, F., Lodder, J., 2002. Two types of lacunar infarcts:
Further arguments from a study on prognosis. Stroke 33, 2072–2076.
de Leeuw, F.E., de Kleine, M., Frijns, C.J., Fijnheer, R., van Gijn, J.,
Kappelle, L.J., 2002. Endothelial cell activation is associated with
cerebral white matter lesions in patients with cerebrovascular disease.
Ann. N. Y. Acad. Sci. 977, 306–314.
Deanfield, J.E., Halcox, J.P., Rabelink, T.J., 2007. Endothelial function and
dysfunction: Testing and clinical relevance. Circulation 115, 1285–
1295.
Farrall, A.J., Wardlaw, J.M., 2009. Blood-brain barrier: Ageing and mi-
crovascular disease--systematic review and meta-analysis. Neurobiol.
Aging 30, 337–352.
Fassbender, K., Bertsch, T., Mielke, O., Mühlhauser, F., Hennerici, M.,
1999. Adhesion molecules in cerebrovascular diseases. Evidence for an
inflammatory endothelial activation in cerebral large- and small-vessel
disease. Stroke 30, 1647–1650.
Fazekas, F., Chawluk, J.B., Alavi, A., Hurtig, H.I., Zimmerman, R.A.,
1987. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and
normal aging. AJR Am. J. Roentgenol. 149, 351–356.
Fuchs, D., Weiss, G., Reibnegger, G., Wachter, H., 1992. The role of
neopterin as a monitor of cellular immune activation in transplantation,
inflammatory, infectious, and malignant diseases. Crit. Rev. Clin. Lab.
Sci. 29, 307–341.
Garde, E., Lykke-Mortensen, E., Rostrup, E., Paulson, O.B., 2005. Decline
in intelligence is associated with progression in white matter hyperin-
tensity volume. J. Neurol. Neurosurg. Psychiatry 76, 1289–1291.
Ghosh, S., May, M.J., Kopp, E.B., 1998. NF-kappa B and Rel proteins:
Evolutionarily conserved mediators of immune responses. Annu. Rev.
Immunol. 16, 225–260.
Gottesman, R.F., Coresh, J., Catellier, D.J., Sharrett, A.R., Rose, K.M.,
Coker, L.H., Shibata, D.K., Knopman, D.S., Jack, C.R., Mosley, T.H.
Jr., 2010. Blood pressure and white-matter disease progression in a
biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study.
Stroke 41, 3–8.
Grau, A.J., Reis, A., Buggle, F., Al-Khalaf, A., Werle, E., Valois, N.,
Bertram, M., Becher, H., Grond-Ginsbach, C., 2001. Monocyte func-
tion and plasma levels of interleukin-8 in acute ischemic stroke. J.
Neurol. Sci. 192, 41–47.
Han, J.H., Wong, K.S., Wang, Y.Y., Fu, J.H., Ding, D., Hong, Z., 2009.
Plasma level of sicam-1 is associated with the extent of white matter
lesion among asymptomatic elderly subjects. Clin. Neurol. Neurosurg.
111, 847–851.
Hassan, A., Hunt, B.J., O’Sullivan, M., Parmar, K., Bamford, J.M., Briley,
D., Brown, M.M., Thomas, D.J., Markus, H.S., 2003. Markers of
endothelial dysfunction in lacunar infarction and ischaemic leukoarai-
osis. Brain 126, 424–432.Henskens, L.H., Kroon, A.A., van Oostenbrugge, R.J., Gronenschild, E.H.,
Fuss-Lejeune, M.M., Hofman, P.A., Lodder, J., de Leeuw, P.W., 2008.
Increased aortic pulse wave velocity is associated with silent cerebral
small-vessel disease in hypertensive patients. Hypertension 52, 1120–
1126.
Hoffmann, G., 2007. More on: Neopterin induces the proatherothrombotic
phenotype in human coronary endothelial cells. J. Thromb. Haemost. 5,
211–212.
Knottnerus, I.L., Ten Cate, H., Lodder, J., Kessels, F., van Oostenbrugge,
R.J., 2009. Endothelial dysfunction in lacunar stroke: A systematic
review. Cerebrovasc. Dis. 27, 519–526.
Lind, L., 2003. Circulating markers of inflammation and atherosclerosis.
Atherosclerosis 169, 203–214.
Markus, H.S., Hunt, B., Palmer, K., Enzinger, C., Schmidt, H., Schmidt,
R., 2005. Markers of endothelial and hemostatic activation and pro-
gression of cerebral white matter hyperintensities: Longitudinal results
of the austrian stroke prevention study. Stroke 36, 1410–1414.
Muller Kobold, A.C., Kallenberg, C.G., Tervaert, J.W., 1999. Monocyte
activation in patients with wegener’s granulomatosis. Ann. Rheum.
Dis. 58, 237–245.
Poggesi, A., Pracucci, G., Chabriat, H., Erkinjuntti, T., Fazekas, F., Ver-
delho, A., Hennerici, M., Langhorne, P., O’Brien, J., Scheltens, P.,
Visser, M.C., Crisby, M., Waldemar, G., Wallin, A., Inzitari, D.,
Pantoni, L., Leukoaraiosis And DISability Study Group, 2008. Urinary
complaints in nondisabled elderly people with age-related white matter
changes: The Leukoaraiosis And DISability (LADIS) study. J. Am.
Geriatr. Soc. 56, 1638–1643.
Reed, B.R., Eberling, J.L., Mungas, D., Weiner, M., Kramer, J.H., Jagust,
W.J., 2004. Effects of white matter lesions and lacunes on cortical
function. Arch. Neurol. 61, 1545–1550.
Rothkrantz-Kos, S., Bekers, O., Gubbels, A., Drent, M., Schmitz, M.P.,
van Dieijen-Visser, M.P., 2003. Evaluation of two new high-sensitivity
methods for c-reactive protein. Ann. Clin. Biochem. 40, 398–405.
Rouhl, R.P., van Oostenbrugge, R.J., Knottnerus, I.L., Staals, J.E., Lodder,
J., 2008. Virchow-Robin spaces relate to cerebral small vessel disease
severity. J. Neurol. 255, 692–696.
Rouhl, R.P.W., van Oostenbrugge, R.J., Damoiseaux, J.G.M.C., Debrus-
Palmans, L.L., Theunissen, R.O.M.F.I.H., Knottnerus, I.L.H., Staals,
J.E.A., Delanghe, J.R., Tervaert, J.W., Lodder, J., 2009a. Haptoglobin
phenotype may alter endothelial progenitor cell cluster formation in
cerebral small vessel disease. Curr. Neurovasc Res. 6, 32–41.
Rouhl, R.P.W., Van Oostenbrugge, R.J., Lodder, J., 2009b. White matter
lesions: from present to future, in: Westland, T.B., Calton, R.N. (Eds.),
Handbook on White Matter; Structure, Function and Changes. Nova,
New York, pp. 17–28.
Schmidt, R., Schmidt, H., Pichler, M., Enzinger, C., Petrovic, K., Nieder-
korn, K., Horner, S., Ropele, S., Watzinger, N., Schumacher, M.,
Berghold, A., Kostner, G.M., Fazekas, F., 2006. C-reactive protein,
carotid atherosclerosis, and cerebral small-vessel disease: Results of the
austrian stroke prevention study. Stroke 37, 2910–2916.
Schroecksnadel, K., Frick, B., Winkler, C., Fuchs, D., 2006. Crucial role of
interferon-gamma and stimulated macrophages in cardiovascular dis-
ease. Curr. Vasc. Pharmacol. 4, 205–213.
Schubert, S.Y., Benarroch, A., Monter-Solans, J., Edelman, E.R., 2010.
Monocyte activation state regulates monocyte-induced endothelial pro-
liferation through met signaling. Blood 115, 3407–2412.
Tervaert, J.W., Kallenberg, C.G., 1997. Cell adhesion molecules in vasc-
ulitis. Curr. Opin. Rheumatol. 9, 16–25.
Tullberg, M., Fletcher, E., DeCarli, C., Mungas, D., Reed, B.R., Harvey,
D.J., Weiner, M.W., Chui, H.C., Jagust, W.J., 2004. White matter
lesions impair frontal lobe function regardless of their location. Neu-
rology 63, 246–253.
van Dijk, E.J., Prins, N.D., Vrooman, H.A., Hofman, A., Koudstaal, P.J.,
Breteler, M.M., 2008. Progression of cerebral small vessel disease in
relation to risk factors and cognitive consequences: Rotterdam scan
study. Stroke 39, 2712–2719.
1806 R.P.W. Rouhl et al. / Neurobiology of Aging 33 (2012) 1800–1806van Haelst, P.L., Liem, A., van Boven, A.J., Veeger, N.J., van Veldhuisen,
D.J., Tervaert, J.W., Gans, R.O., Zijlstra, F., 2003. Usefulness of
elevated neopterin and c-reactive protein levels in predicting cardio-
vascular events in patients with non-q-wave myocardial infarction. Am.
J. Cardiol. 92, 1201–1203.
van Straaten, E.C., Fazekas, F., Rostrup, E., Scheltens, P., Schmidt, R.,
Pantoni, L., Inzitari, D., Waldemar, G., Erkinjuntti, T., Mäntylä, R.,
Wahlund, L.O., Barkhof, F., LADIS Group, 2006. Impact of white
matter hyperintensities scoring method on correlations with clinical
data: The LADIS study. Stroke 37, 836–840.
Vernooij, M.W., van der Lugt, A., Ikram, M.A., Wielopolski, P.A., Nies-
sen, W.J., Hofman, A., Krestin, G.P., Breteler, M.M., 2008. Prevalence
and risk factors of cerebral microbleeds: The Rotterdam Scan Study.
Neurology 70, 1208–1214.Wardlaw, J.M., Sandercock, P.A., Dennis, M.S., Starr, J., 2003. Is break-
down of the blood-brain barrier responsible for lacunar stroke, leu-
koaraiosis, and dementia? Stroke 34, 806–812.
Wen, H.M., Mok, V.C., Fan, Y.H., Lam, W.W., Tang, W.K., Wong, A.,
Huang, R.X., Wong, K.S., 2004. Effect of white matter changes on
cognitive impairment in patients with lacunar infarcts. Stroke 35,
1826–1830.
Wiszniewska, M., Devuyst, G., Bogousslavsky, J., Ghika, J., van Melle, G.,
2000. What is the significance of leukoaraiosis in patients with acute
ischemic stroke? Arch. Neurol. 57, 967–973.
Wuerfel, J., Haertle, M., Waiczies, H., Tysiak, E., Bechmann, I., Wer-
necke, K.D., Zipp, F., Paul, F., 2008. Perivascular spaces--MRI
marker of inflammatory activity in the brain? Brain 131, 2332–2340.
